Dendreon to offer end-to-end cell therapy manufacturing

By The Science Advisory Board staff writers

June 16, 2021 -- California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies.

The company is one of only four firms that manufacture cell therapies for commercial use in the U.S. In early 2021, Dendreon started to dedicate capacity for later-stage partner programs within its current infrastructure.


Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter